Edgewise Therapeutics (EWTX) Competitors $14.31 +0.05 (+0.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$14.30 -0.01 (-0.03%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EWTX vs. RYTM, CRSP, AXSM, TLX, LNTH, PCVX, MTSR, CYTK, MRUS, and KRYSShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), Lantheus (LNTH), Vaxcyte (PCVX), Metsera (MTSR), Cytokinetics (CYTK), Merus (MRUS), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Its Competitors Rhythm Pharmaceuticals CRISPR Therapeutics Axsome Therapeutics Telix Pharmaceuticals Lantheus Vaxcyte Metsera Cytokinetics Merus Krystal Biotech Rhythm Pharmaceuticals (NASDAQ:RYTM) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Which has more volatility and risk, RYTM or EWTX? Rhythm Pharmaceuticals has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Do analysts prefer RYTM or EWTX? Rhythm Pharmaceuticals presently has a consensus price target of $91.93, suggesting a potential upside of 4.11%. Edgewise Therapeutics has a consensus price target of $40.55, suggesting a potential upside of 183.34%. Given Edgewise Therapeutics' higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91 Which has better valuation & earnings, RYTM or EWTX? Edgewise Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M43.17-$260.60M-$2.81-31.42Edgewise TherapeuticsN/AN/A-$133.81M-$1.55-9.23 Is RYTM or EWTX more profitable? Edgewise Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -123.26%. Edgewise Therapeutics' return on equity of -30.95% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-123.26% -739.62% -44.27% Edgewise Therapeutics N/A -30.95%-29.45% Does the media favor RYTM or EWTX? In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 12 mentions for Rhythm Pharmaceuticals and 10 mentions for Edgewise Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 0.78 beat Edgewise Therapeutics' score of 0.64 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEdgewise Therapeutics beats Rhythm Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50B$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-9.2317.6228.6723.80Price / SalesN/A179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book2.968.508.275.55Net Income-$133.81M-$55.06M$3.24B$259.03M7 Day Performance1.35%-3.98%-3.69%-4.59%1 Month Performance9.99%9.59%4.33%4.46%1 Year Performance-11.94%6.72%25.95%18.03% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics2.2917 of 5 stars$14.31+0.4%$40.55+183.3%-14.6%$1.50BN/A-9.2360News CoverageUpcoming EarningsAnalyst ForecastRYTMRhythm Pharmaceuticals3.4446 of 5 stars$88.63-0.6%$91.93+3.7%+88.5%$5.68B$130.13M-31.54140Upcoming EarningsInsider TradeCRSPCRISPR Therapeutics2.7909 of 5 stars$65.33+0.3%$71.75+9.8%+2.3%$5.62B$35M-14.45460Upcoming EarningsAnalyst RevisionGap UpHigh Trading VolumeAXSMAxsome Therapeutics4.8236 of 5 stars$109.68-1.8%$172.33+57.1%+19.8%$5.50B$385.69M-19.01380Positive NewsUpcoming EarningsTLXTelix PharmaceuticalsN/A$16.50+1.7%$22.33+35.4%N/A$5.49B$516.72M0.00N/AGap DownHigh Trading VolumeLNTHLantheus4.6193 of 5 stars$71.56+2.0%$131.20+83.3%-28.4%$4.86B$1.53B20.33700News CoverageUpcoming EarningsAnalyst RevisionPCVXVaxcyte2.2389 of 5 stars$35.64-1.6%$136.50+283.0%-58.0%$4.67BN/A-8.93160News CoveragePositive NewsUpcoming EarningsMTSRMetseraN/A$39.91-6.6%$55.00+37.8%N/A$4.49BN/A0.0081News CoverageEarnings ReportLockup ExpirationAnalyst RevisionGap UpCYTKCytokinetics4.0154 of 5 stars$36.96-0.7%$70.92+91.9%-36.6%$4.45B$18.47M-6.99250News CoverageUpcoming EarningsAnalyst ForecastInsider TradeMRUSMerus2.9208 of 5 stars$62.37-1.4%$84.64+35.7%+25.1%$4.38B$54.73M-15.2937News CoverageKRYSKrystal Biotech4.8885 of 5 stars$148.09+0.4%$213.75+44.3%-21.0%$4.26B$290.52M35.60210Upcoming Earnings Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors CRISPR Therapeutics Competitors Axsome Therapeutics Competitors Telix Pharmaceuticals Competitors Lantheus Competitors Vaxcyte Competitors Metsera Competitors Cytokinetics Competitors Merus Competitors Krystal Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EWTX Stock Alerts